Mizuho analyst Anthony Petrone raised the firm’s price target on Lantheus (LNTH) to $95 from $85 and keeps an Outperform rating on the shares. The firm adjusted estimates and price targets for several names in its medical devices and diagnostics coverage ahead of Q1 earnings from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LNTH:
- Lantheus announces three-month extension of LNTH-2501 PDUFA date
- Lantheus price target raised to $110 from $105 at Jefferies
- Lantheus announces FDA approval of Pylarify TruVu injection
- Lantheus receives U.S. FDA tentative approval for Lutetium Lu 177
- Lantheus price target raised to $89 from $82 at Truist